These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Temporal Trends in Diagnostic Testing Patterns for Wild-Type Transthyretin Amyloid Cardiomyopathy in the Medicare Fee-for-Service Population. Bourque JM; Schepart A; Bhambri R; Castaño A; O'Brien A; Chen Y; Prasad S; Roy A; Grodin JL Am J Cardiol; 2022 Mar; 167():98-103. PubMed ID: 35022130 [TBL] [Abstract][Full Text] [Related]
23. Estimating cancer risk from Einstein AJ; Shuryak I; Castaño A; Mintz A; Maurer MS; Bokhari S J Nucl Cardiol; 2020 Feb; 27(1):215-224. PubMed ID: 29850972 [TBL] [Abstract][Full Text] [Related]
24. A case of disappearing amyloid on technetium pyrophosphate scan. Wang A; Mahmood U; Tang X; Jain D; Pan S J Nucl Cardiol; 2023 Oct; 30(5):1986-1991. PubMed ID: 37340232 [TBL] [Abstract][Full Text] [Related]
25. Wild type cardiac amyloidosis: is it time to order a nuclear technetium pyrophosphate SPECT imaging study? Shen CP; Vanichsarn CT; Pandey AC; Billick K; Rubenson DS; Mohan RC; Heywood JT; Srivastava AV Int J Cardiovasc Imaging; 2023 Jan; 39(1):201-208. PubMed ID: 36598681 [TBL] [Abstract][Full Text] [Related]
26. Towards a Diagnosis of Cardiac Amyloidosis: Single Center Experience with Saleem M; Sadat B; Van Harn M; Ananthasubramaniam K Medicina (Kaunas); 2023 Feb; 59(2):. PubMed ID: 36837580 [No Abstract] [Full Text] [Related]
27. [Noninvasive diagnosis of cardiac involvement by technetium-99m-pyrophosphate (Tc-99m PYP) myocardial scintigraphy in 2 cases of familial amyloid polyneuropathy and 1 case of secondary amyloidosis]. Takezaki M; Ishida Y; Morozumi T; Tani A; Sato H; Hori M; Kitabatake A; Kamada T; Kimura K; Kozuka T Kaku Igaku; 1989 Dec; 26(12):1537-43. PubMed ID: 2560088 [TBL] [Abstract][Full Text] [Related]
28. "Loss of Bone Signal" on 99m Tc-Labeled Pyrophosphate Scintigraphy in a Patient With Wild-Type Transthyretin Amyloidosis. Takahashi K; Sasaki D; Iwamura T; Sakaue T; Okura T Clin Nucl Med; 2024 Aug; 49(8):767-770. PubMed ID: 38651784 [TBL] [Abstract][Full Text] [Related]
29. Utility of Tsutsui Y; Kubota T; Kato S; Nozoe M; Suematsu N; Okabe M; Yamamoto Y; Tsutsui H Circ Rep; 2019 Jun; 1(7):277-285. PubMed ID: 33693151 [No Abstract] [Full Text] [Related]
30. False positive technetium-99m pyrophosphate scintigraphy in a patient with cardiac amyloidosis light chain: Case report. Zeng Y; Poterucha TJ; Einstein AJ; Zhang Q; Chen Y; Xie H; Wan K; Liang Y; Chen J; Tang G Medicine (Baltimore); 2021 Apr; 100(17):e25582. PubMed ID: 33907108 [TBL] [Abstract][Full Text] [Related]
31. Cardioprotective Effect of Paricalcitol on Amitriptyline-Induced Cardiotoxicity in Rats: Comparison of [ Aygun H; Basol N; Gul SS Cardiovasc Toxicol; 2020 Aug; 20(4):427-436. PubMed ID: 32219715 [TBL] [Abstract][Full Text] [Related]
34. Serial scanning with Minutoli F; Di Bella G; Mazzeo A; Laudicella R; Gentile L; Russo M; Vita G; Baldari S J Nucl Cardiol; 2021 Oct; 28(5):1949-1957. PubMed ID: 31741327 [TBL] [Abstract][Full Text] [Related]
35. Direct comparison of diagnostic and clinical values between Tc-99 m DPD and Tc-99 m PYP scintigraphy in patients with cardiac amyloidosis. Park YJ; Lee J; Kim D; Choi JO; Kim SJ; Kim K; Choi JY BMC Med Imaging; 2023 Jul; 23(1):92. PubMed ID: 37460984 [TBL] [Abstract][Full Text] [Related]
36. Extracardiac Biopsy Sensitivity in Transthyretin Amyloidosis Cardiomyopathy Patients With Positive Nishi M; Takashio S; Morioka M; Fujiyama A; Nakashima N; Hirakawa K; Hanatani S; Usuku H; Yamamoto E; Kidoh M; Oda S; Gushima R; Matsushita K; Fukushima S; Ueda M; Tsujita K Circ J; 2022 Jun; 86(7):1113-1120. PubMed ID: 35599006 [TBL] [Abstract][Full Text] [Related]
37. Comparison of planar with tomographic pyrophosphate scintigraphy for transthyretin cardiac amyloidosis: Perils and pitfalls. Asif T; Gomez J; Singh V; Doukky R; Nedeltcheva A; Malhotra S J Nucl Cardiol; 2021 Feb; 28(1):104-111. PubMed ID: 32901418 [TBL] [Abstract][Full Text] [Related]
38. Role of (99m)Tc-DPD scintigraphy in diagnosis and prognosis of hereditary transthyretin-related cardiac amyloidosis. Rapezzi C; Quarta CC; Guidalotti PL; Pettinato C; Fanti S; Leone O; Ferlini A; Longhi S; Lorenzini M; Reggiani LB; Gagliardi C; Gallo P; Villani C; Salvi F JACC Cardiovasc Imaging; 2011 Jun; 4(6):659-70. PubMed ID: 21679902 [TBL] [Abstract][Full Text] [Related]
39. The Association of Cardiac Biomarkers, the Intensity of Tc99 Pyrophosphate Uptake, and Survival in Patients Evaluated for Transthyretin Cardiac Amyloidosis in the Early Therapeutics Era. Martyn T; Saef J; Hussain M; Ives L; Kiang A; Estep JD; Collier P; Starling RC; Cremer PC; Tang WHW; Hanna M; Jaber WA J Card Fail; 2022 Oct; 28(10):1509-1518. PubMed ID: 35843490 [TBL] [Abstract][Full Text] [Related]